Search

for
Search:

GlossaryMyotonic Dystrophy Type 1

genetic disorder causing progressive muscle wasting and weakness

Myotonic Dystrophy Type 1 (DM1), also known as Steinert disease, is a genetic disorder characterized by progressive muscle wasting and weakness. It is caused by a mutation in the DMPK gene, leading to an abnormal expansion of DNA repeats that disrupts normal cellular function. Symptoms can include muscle stiffness (myotonia), cataracts, heart conduction defects, and endocrine changes, and the severity can vary widely among individuals.

Related Terms

Sort by

Community Join

30 / 1000+ results

community DHT Isn’t the Only Factor in Hair Loss and That Might Be the Key to a Real Cure

in Research/Science 368 upvotes 1 month ago

Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.

community MCL1 does anyone knows anthying about it

in Research/Science 9 upvotes 1 year ago

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

community TWIST-1 and the cure: Is it really that easy?

in Research/Science 283 upvotes 3 years ago

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

community Twist1 Group Buy: Yes it’s that easy

in Research/Science 39 upvotes 3 years ago

A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.

community HLT Megathread on HMI-115 (key takeaways in comments)

in Research/Science 39 upvotes 3 years ago

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

community Masseter Muscles and the Tension Theory of Baldness

in Treatment 5 upvotes 5 years ago

The conversation discusses the tension theory of baldness, suggesting that over-developed masseter muscles may harm hair follicles. Botox injections to relax these muscles reportedly led to an 18% increase in hair count in men with AGA.

community Why creatine and gym cause MPD

in Finasteride/Dutasteride 2 years ago

Gym and creatine can cause hair loss by increasing testosterone and androgenic activity. DHT blockers may help some, while others need androgen suppression with topical AA like RU or Pyri.

community Phase II Clinical Trial for TDM-105795 started recruiting

in Research/Science 23 upvotes 3 years ago

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

community DUPA, Non Responders and Connective Tissue Disorders

in Research/Science 9 upvotes 10 months ago

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

community Interesting new publication suggesting that MPB should be assessed as a early warning sign for type-2 diabetes.

15 upvotes 8 years ago

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

community GT20029. Kintor Pharma’s Product

in Research/Science 12 upvotes 3 years ago

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

community Occipitalis Muscle Tension Theory

in Treatment 9 upvotes 2 months ago

Scalp tension from the occipitalis muscle is theorized to contribute to hair loss, but most believe DHT and genetics are the main causes. Treatments like finasteride and minoxidil are considered more effective than addressing scalp tension.

community GT20029: How It Works for Hair Loss - Hair Loss “Cure”

in Research/Science 36 upvotes 2 months ago

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

community TDM-105795 phase 2 results are in!

in Research/Science 29 upvotes 2 years ago

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

community IGE Hair Loss and Miniaturization

in Chat 3 upvotes 1 year ago

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

community ET-02 Now Recruiting in Texas for Phase 1

in Research/Science 20 upvotes 1 year ago

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

community Pyrilutamide ,the molecule’s true nature

in Research 302 upvotes 1 year ago

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

community Whats the deal with TDM-105795?

in Research/Science 4 upvotes 1 month ago

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

community Has anyone used Magnesium L-Threonate ?

70 upvotes 7 years ago

Magnesium L-Threonate may help treat balding by reducing DKK-1 expression without affecting DHT. Users discuss its potential effectiveness and application methods, with some considering trying it topically.

community The Effect of Intradermal Botox on Androgenetic Alopecia and Its Possible Mechanism (Journal of the American Academy of Dermatology (2020)

in Treatment 12 upvotes 5 years ago

Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.

community 5ar Type I in the frontal hair follicles - Dutasteride

in Finasteride/Dutasteride 21 upvotes 1 year ago

The conversation discusses that dutasteride may be more effective than finasteride for frontal hair loss due to higher 5ar Type 1 enzyme activity in that area. Some users question the validity of this information, while others confirm it with additional sources.

community Anagenic is trying to compound Gt20029

in Treatment 58 upvotes 3 years ago

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

community [Nov 2019] The peptide AC 2 isolated from Bacillus-treated Trapa japonica fruit extract rescues DHT (dihydrotestosterone)-treated human dermal papilla cells and mediates mTORC1 signaling for autophagy and apoptosis suppression

23 upvotes 6 years ago

A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.

community What is preventing GT20029 from being the cure to androgenetic hair loss?

in Research/Science 10 upvotes 8 months ago

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

community Kintor’s GT20029 Phase 1 success

in Update 73 upvotes 3 years ago

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively

in Research/Science 37 upvotes 3 years ago

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi

in Treatment 14 upvotes 6 years ago

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

community IGF-1 and Peptides? Miracle molecule waiting to be found

in Research/Science 10 upvotes 7 months ago

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

community Temporalis Hypertrophy and hair loss

in Treatment 24 upvotes 10 months ago

Hair loss treatments include finasteride, minoxidil, and scalp exercises. Opinions vary on the effectiveness, with some attributing hair loss to muscle tension and inflammation, while others focus on genetics and DHT.

community PP405 Identity Research

in Research 292 upvotes 8 months ago

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.